AIM: To explore the potential usefulness of serum miR-122 and miR-221 as non-invasive diagnostic markers of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). METHODS: This prospective study was conducted on 90 adult patients of both sex with HCV-related chronic liver disease and chronic hepatitis C related HCC. In addition to the 10 healthy control individuals, patients were stratified into; interferon-naïve chronic hepatitis C (CH) (n = 30), post-hepatitis C compensated cirrhosis (LC) (n = 30) and treatment-naïve HCC (n = 30). All patients and controls underwent full clinical assessment and laboratory investigations in addition to the evaluation of the level of serum miRNA expression by RT-PCR. RESULTS: There was a significant fold change in serum miRNA expression in the different patient groups when compared to normal controls; miR-122 showed significant fold increasing in both CH and HCC and significant fold decrease in LC. On the other hand, miR-221 showed significant fold elevation in both CH and LC groups and significant fold decrease in HCC group (P = 0.01). Comparing fold changes in miRNAs in HCC group vs non HCC group (CH and Cirrhosis), there was non-significant fold elevation in miR-122 (P = 0.21) and significant fold decreasing in miR-221 in HCC vs non-HCC (P = 0.03). ROC curve analysis for miR-221 yielded 87% sensitivity and 40% specificity for the differentiation of HCC patients from non-HCC at a cutoff 1.82. CONCLUSION: Serum miR-221 has a strong potential to serve as one of the novel non-invasive biomarkers of HCC.
AIM: To explore the potential usefulness of serum miR-122 and miR-221 as non-invasive diagnostic markers of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). METHODS: This prospective study was conducted on 90 adult patients of both sex with HCV-related chronic liver disease and chronic hepatitis C related HCC. In addition to the 10 healthy control individuals, patients were stratified into; interferon-naïve chronic hepatitis C (CH) (n = 30), post-hepatitis C compensated cirrhosis (LC) (n = 30) and treatment-naïve HCC (n = 30). All patients and controls underwent full clinical assessment and laboratory investigations in addition to the evaluation of the level of serum miRNA expression by RT-PCR. RESULTS: There was a significant fold change in serum miRNA expression in the different patient groups when compared to normal controls; miR-122 showed significant fold increasing in both CH and HCC and significant fold decrease in LC. On the other hand, miR-221 showed significant fold elevation in both CH and LC groups and significant fold decrease in HCC group (P = 0.01). Comparing fold changes in miRNAs in HCC group vs non HCC group (CH and Cirrhosis), there was non-significant fold elevation in miR-122 (P = 0.21) and significant fold decreasing in miR-221 in HCC vs non-HCC (P = 0.03). ROC curve analysis for miR-221 yielded 87% sensitivity and 40% specificity for the differentiation of HCC patients from non-HCC at a cutoff 1.82. CONCLUSION: Serum miR-221 has a strong potential to serve as one of the novel non-invasive biomarkers of HCC.
Authors: Erin Connolly; Margherita Melegari; Pablo Landgraf; Tatyana Tchaikovskaya; Bud C Tennant; Betty L Slagle; Leslie E Rogler; Mihaela Zavolan; Thomas Tuschl; Charles E Rogler Journal: Am J Pathol Date: 2008-08-07 Impact factor: 4.307
Authors: G Fattovich; G Giustina; J Sanchez-Tapias; C Quero; A Mas; P G Olivotto; A Solinas; P Almasio; S Hadziyannis; F Degos; M C de Moura; K Krogsgaard; M Pantalena; G Realdi; R Corrocher; S W Schalm Journal: Am J Gastroenterol Date: 1998-06 Impact factor: 10.864
Authors: Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz Journal: Gastroenterology Date: 2009-04-09 Impact factor: 22.682
Authors: Yu Wang; Alvin T C Lee; Joel Z I Ma; Jingbo Wang; Jianwei Ren; Yuchen Yang; Erwin Tantoso; Kuo-Bin Li; London L P J Ooi; Patrick Tan; Caroline G L Lee Journal: J Biol Chem Date: 2008-03-04 Impact factor: 5.157
Authors: Abdel-Rahman Nabawy Zekri; Amira Salah El-Din Youssef; Eman Desouky El-Desouky; Ola Sayed Ahmed; Mai M Lotfy; Auhood Abdel-Monem Nassar; Abeer A Bahnassey Journal: Tumour Biol Date: 2016-06-06